back to publ. 15

31.Peracchi, A. 2004. Prospects for antiviral ribozymes and deoxyribozymes.Reviews in Medical Virology 14(14):47-64.
30.Yaghootfam, A., Gieselmann, V 2003. Specific hammerhead ribozymes reduce synthesis of cation-independent mannose 6-phosphate receptor mRNA and protein Gene Therapy. 10(11):1567-1574
29.Cairns, M. J., A. King, and L. Q. Sun. 2003. Optimisation of the 10-23 DNAzyme-substrate pairing interactions enhanced RNA cleavage activity at purine-cytosine target sites. Nucleic Acids Research. 31(11):2883-2889.
28.Langlois, M. A., N. S. Lee, J. J. Rossi, and J. Puymirat. 2003. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Molecular Therapy. 7(5):670-680.
27.Morrissey, D. V., P. A. Lee, D. A. Johnson, S. L. Overly, J. A. McSwiggen, L. Beigelman, V. R. Mokler, L. Maloney, C. Vargeese, K. Bowman, J. T. O'Brien, C. S. Shaffer, A. Conrad, P. Schmid, J. D. Morrey, D. G. Macejak, P. A. Pavco, and L. M. Blatt. 2002. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. Journal of Viral Hepatitis. 9(6):411-418.
26.Lyngstadaas, S. P. 2001. Synthetic hammerhead ribozymes as tools in gene expression. Critical Reviews in Oral Biology & Medicine. 12(6):469-478.
25.Eckstein, F., A. R. Kore, and K. L. Nakamaye. 2001. In vitro selection of hammerhead ribozyme sequence variants. Chembiochem. 2(9):629-635.
24.Beckley, S. A., P. Liu, M. L. Stover, S. I. Gunderson, A. C. Lichtler, and D. W. Rowe. 2001. Reduction of target gene expression by a modified U1 snRNA. Molecular and Cellular Biology. 21(8):2815-2825.
23.Eckstein, F., and B. Bramlage. 1999. The hammerhead ribozyme. Biopolymers. 52(3):147-154.
22.Propsting, M. J., S. Kubicka, J. Genschel, M. P. Manns, H. Lochs, and H. H. J. Schmidt. 2000. Inhibition of transthyretin-met30 expression using Inosine(15.1)-Hammerhead ribozymes in cell culture. Biochemical and Biophysical Research Communications. 279(3):970-973.
21.Amarzguioui, M., G. Brede, E. Babaie, M. Grotli, B. Sproat, and H. Prydz. 2000. Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes. Nucleic Acids Research. 28(21):4113-4124.
20.Caselmann, W. H., M. Serwe, T. Lehmann, J. Ludwig, B. S. Sproat, and J. W. Engels. 2000. Design, delivery and efficacy testing to therapeutic nucleic acids used to inhibit hepatitis C virus gene expression in vitro and in vivo. World Journal of Gastroenterology. 6(5):626-629.
19.Matulic-Adamic, J., and L. Beigelman. 2000. An improved synthesis of inosine 3 '-phosphoramidite. Synthetic Communications. 30(21):3963-3969.
18.Kore, A. R., N. K. Vaish, J. A. Morris, and F. Eckstein. 2000. In vitro evolution of the hammerhead ribozyme to a purine- specific ribozyme using mutagenic PCR with two nucleotide analogues. Journal of Molecular Biology. 301(5):1113-1121.
17.Sun, L. Q., M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach. 2000. Catalytic nucleic acids: From lab to applications. Pharmacological Reviews. 52(3):325-347.
16.Goodchild, J. 2000. Hammerhead ribozymes: Biochemical and chemical considerations. Current Opinion in Molecular Therapeutics. 2(3):272-281.
15.Kore, A. R., C. Carola, and F. Eckstein. 2000. Attempts to obtain more efficient GAC-cleaving hammerhead ribozymes by in vitro selection. Bioorganic & Medicinal Chemistry. 8(7):1767-1771.
14.Dunkel, M., and V. Reither. 2000. Replacement of the phosphodiester bond between U4 and G5 in the U-turn of a chemically modified hammerhead ribozyme by an amide bond. Nucleosides Nucleotides & Nucleic Acids. 19(4):749-756.
13.Salmi, P., B. S. Sproat, J. Ludwig, R. Hale, N. Avery, J. Kela, and C. Wahlestedt. 2000. Dopamine D-2 receptor ribozyme inhibits quinpirole-induced stereotypy in rats. European Journal of Pharmacology. 388(1):R1-R2.
12.Giles, R. V., D. G. Spiller, R. E. Clark, and D. M. Tidd. 1999. Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet-targeting ribozymes. Nucleosides & Nucleotides. 18(9):1935-1944.
11.Ludwig, J., M. Blaschke, M. Dunkel, B. Beijer, K. Ross, and B. S. Sproat. 1999. Structural requirements at the 15.1-16.1 position of the hammerhead ribozyme. Nucleosides & Nucleotides. 18(6-7):1519-1520.
10.Hammann, C., and M. Tabler. 1999. Generation and application of asymmetric hammerhead ribozymes. Methods-a Companion to Methods in Enzymology. 18(3):273-280.
9.Propsting, M. J., M. Blaschke, R. E. Haas, J. Genschel, H. J. Hedrich, M. P. Manns, and H. H. J. Schmidt. 1999. Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochemical and Biophysical Research Communications. 260(2):313-317.
8.Carola, C., and F. Eckstein. 1999. Nucleic acid enzymes. Current Opinion in Chemical Biology. 3(3):274-283.
7.Sproat, B. S., T. Rupp, N. Menhardt, D. Keane, and B. Beijer. 1999. Fast and simple purification of chemically modified hammerhead ribozymes using a lipophilic capture tag. Nucleic Acids Research. 27(8):1950-1955.
6.Dunkel, M., and V. Reither. 1999. Synthesis of 2 '-C-alpha-difluoromethylarauridine and its 3 '- O-phosphoramidite incorporation into a hammerhead ribozyme. Bioorganic & Medicinal Chemistry Letters. 9(5):787-792.
5.Vaish, N. K., A. R. Kore, and F. Eckstein. 1998. Recent developments in the hammerhead ribozyme field. Nucleic Acids Research. 26(23):5237-5242.
4.Amarzguioui, M., and H. Prydz. 1998. Hammerhead ribozyme design and application. Cellular and Molecular Life Sciences. 54(11):1175-1202.
3.Earnshaw, D. J., and M. J. Gait. 1998. Modified oligoribonucleotides as site-specific probes of RNA structure and function. Biopolymers. 48(1):39-55.
2.Kore, A. R., N. K. Vaish, U. Kutzke, and F. Eckstein. 1998. Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. Nucleic Acids Research. 26(18):4116-4120.
1.Burke, J. F., and S. M. Thomas. 1998. Ribozyme: RNA as an enzyme, but as a therapeutic? Expert Opinion On Therapeutic Patents. 8(9):1093-1097.